SciSparc Ltd., a clinical-stage pharmaceutical company, announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase IIb clinical trial of SCI-110, aimed at treating Tourette Syndrome (TS). The trial is set to take place at three renowned institutions: Yale Child Study Center at Yale School of Medicine in the USA, Hannover Medical School in Germany, and Tel Aviv Sourasky Medical Center in Israel. Institutional Review Board approvals have been obtained from all sites, along with necessary approvals from the Israeli Ministry of Health and the Federal Institute for Drugs and Medical Devices in Germany. The trial will assess the efficacy, safety, and tolerability of SCI-110 in adults aged 18 to 65, comparing the drug to a placebo using the Yale Global Tic Severity Scale. SciSparc's CEO, Oz Adler, expressed confidence in SCI-110's potential to change the treatment landscape for TS. The company also has other drug development programs based on cannabinoid pharmaceuticals for various conditions.

SciSparc Ltd., a clinical-stage pharmaceutical company, announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase IIb clinical trial of SCI-110, aimed at treating Tourette Syndrome (TS). The trial is set to take place at three renowned institutions: Yale Child Study Center at Yale School of Medicine in the USA, Hannover Medical School in Germany, and Tel Aviv Sourasky Medical Center in Israel. Institutional Review Board approvals have been obtained from all sites, along with necessary approvals from the Israeli Ministry of Health and the Federal Institute for Drugs and Medical Devices in Germany. The trial will assess the efficacy, safety, and tolerability of SCI-110 in adults aged 18 to 65, comparing the drug to a placebo using the Yale Global Tic Severity Scale. SciSparc's CEO, Oz Adler, expressed confidence in SCI-110's potential to change the treatment landscape for TS. The company also has other drug development programs based on cannabinoid pharmaceuticals for various conditions.